Breaking Finance News

SAGE Therapeutics Inc (NASDAQ:SAGE) target price raised to $68.00, issued a report today by Leerink Swann

SAGE Therapeutics Inc (NASDAQ:SAGE) had its target price raised to $68.00 by Leerink Swann in a report released 10/04/2016. The new target price indicates a possible upside of 0.46% based on the company's last stock close price.

Previously on 09/13/2016, Raymond James reported about SAGE Therapeutics Inc (NASDAQ:SAGE) raised the target price from $0.00 to $75.00. At the time, this indicated a possible upside of 0.85%.

Yesterday SAGE Therapeutics Inc (NASDAQ:SAGE) traded 0.74% higher at $46.43. The company’s 50-day moving average is $41.04 and its 200-day moving average is $36.72. The last stock close price is up 25.23% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 256,162 shares of the stock were exchanged, down from an average trading volume of 977,892

See Chart Below

SAGE Therapeutics Inc (NASDAQ:SAGE)

SAGE Therapeutics Inc has a 52 week low of $26.28 and a 52 week high of $62.64 The company’s market cap is currently $0.

In addition to Leerink Swann reporting its target price, a total of 8 firms have issued a report on the stock. The consensus target price is $68.88 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About SAGE Therapeutics Inc (NASDAQ:SAGE)

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *